D
David Michelson
Researcher at Merck & Co.
Publications - 144
Citations - 10624
David Michelson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Placebo & Atomoxetine. The author has an hindex of 51, co-authored 143 publications receiving 9597 citations. Previous affiliations of David Michelson include University of Nebraska Medical Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
David Michelson,Douglas E. Faries,Joachim F. Wernicke,Douglas Kelsey,Katherine Kendrick,F. Randy Sallee,Thomas J. Spencer +6 more
TL;DR: Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms.
Journal ArticleDOI
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.
David Michelson,Lenard A. Adler,Thomas J. Spencer,Frederick W. Reimherr,Scott A. West,Albert J. Allen,Douglas Kelsey,Joachim F. Wernicke,Anthony Dietrich,Denái R. Milton +9 more
TL;DR: Atomoxetine appears to be an efficacious treatment for adult ADHD, and its lack of abuse potential may be an advantage for many patients.
Journal ArticleDOI
Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study
David Michelson,Albert J. Allen,Joan Busner,Charles D. Casat,David W. Dunn,Christopher J. Kratochvil,Jeffrey H. Newcorn,F. Randy Sallee,R. Bart Sangal,Keith E. Saylor,Scott West,Douglas Kelsey,Joachim F. Wernicke,Nancy J. Trapp,Donald Harder +14 more
TL;DR: Once-daily administration of atomoxetine is an effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD) as assessed by investigator, parent, and teacher ratings.
Journal ArticleDOI
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia.
Leslie J. Crofford,Stanley R. Pillemer,Konstantine T. Kalogeras,Joseph M. Cash,David Michelson,Mitchel A. Kling,Esther M. Sternberg,Philip W. Gold,George P. Chrousos,Ronald L. Wilder +9 more
TL;DR: The view that HPA axis function is perturbed in patients with FM is supported, with a significant decrease in net integrated cortisol response to oCRH in FM patients, indicating adrenal hyporesponsiveness.
Journal ArticleDOI
Bone Mineral Density in Women with Depression
David Michelson,Constantine A. Stratakis,Lauren Hill,James D. Reynolds,Elise Galliven,George P. Chrousos,Philip W. Gold +6 more
TL;DR: Past or current depression in women is associated with decreased bone mineral density, and women with past or current major depression have demonstrable decreases in bone density.